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Abstract
Objective—Toex amine US physicians’ self-reported knowledge about the Polypill, factors
considered in deciding whether to prescribe it, and acceptance of prescribing it for cardiovascular
disease (CVD)prevention.
Methods—Numerical scales of 0 (lowest) to 5 (highest) were used to assess self -reported
knowledge and importance of factors relevant to making a decision to prescribe a Polypill.
Characteristics of physicians indicating they would prescribe a Polypill were compared.
Results—Among 952 physicians surveyed February through March 2010, mean self-rated
knowledge about the Polypill was 2.0±1.5. Importance of degree of CVD event reduction, cost,
and side effects were rated with means of 4.4, 4.3, and 4.3, respectively. 83% of respondents
indicated they would “definitely” or “probably” prescribe it for high-risk patients; 62% would do
so for moderate risk patients. Physicians with self-rated knowledge at ≥75th percentile were more
likely to indicate they would prescribe a Polypill for moderate risk ( adjusted OR 2.16; 95% CI
1.60–2.93) and high-risk (adjusted OR 1.57; 95% CI 1.07–2.32) patients.
Conclusion—Among this sample of physicians, there is relatively high acceptance of
prescribing a Polypill for CVD prevention despite relatively modest knowledge about it.
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Cardiovascular disease (CVD) accounts for 1 of every 3 deaths in the United States (US),
(Lloyd-Jones et al, 2009). Prevention of CVD therefore remains a high public health
priority, and the high-rate of initial CVD events that are fatal or disabling makes primary
prevention paramount. The conventional clinical approach to primary prevention of CVD
relies on identification and treatment of individual threshold-based risk factors such as
hyperlipidemia and hypertension. However, a sizeable proportion of CVD events occur
among people with average levels of blood pressure (BP) and cholesterol(Law et al, 2004;
Rose 1985 ; Wald and Law 2003). This “prevention paradox” occurs because there are many
more people in the middle of the distribution of these risk factors(Rose 1985) .
An approach of only offering preventive pharmacotherapy to people with elevated risk
factors based on the upper tail of the distribution does not take into full account the
consistent increase in relative risk of CVD as BP or cholesterol increases, the combined
effects of risk factors, or the fact that the strongest risk factor is age( Hingorani and Psaty,
2009; Lewington et al, 2002; Lewington et al, 2007; Rose 1985). An exclusive risk factor
level approach therefore does little to help reduce the risk in the large portion of the
population whose overall CVD risk is elevated but whose individual risk factors are only
mildly elevated or “normal” (Hingorani and Psaty, 2009; Law et al, 2004; Persell et al,
2006).
In 2003 Wald and Law proposed a strategy to address this significant limitation of the
clinical approach to CVD prevention(Wald and Law, 2003) . They calculated that if a
combination pill containing three half-standard doses of BP-lowering drugs, a statin
(standard dose), low-dose aspirin, and folic acid was given to all adults 55 years and
older(regardless of risk factor levels), the potential impact would be substantial, with
reductions in coronary heart disease and stroke events of 80% and 88%, respectively .
However, the actual efficacy of a population-level Polypill approach in reducing CVD
events is unknown. Calculations based on data observed in The Indian Polycap Study (TIPS)
suggest a risk reduction closer to 60%—still a tremendous potential impact (The Indian
Polycap Study, 2009).
With the publication of TIPS, ongoing initial research in several countries, and at least three
Indian pharmaceutical companies currently producing versions of a Polypill, it appears that
the Polypill-type approach may become a viable option for CVD prevention, but additional
studies are needed( Combination Pharmacotherapy and Public Health Research Working
Group, 2005; Hingorani and Psaty, 2009; Wald and Wald, 2010). Currently, however, there
are no Polypill trials in the US, and physician acceptance of a population-level Polypill
approach may be limited by concerns such as potential side effects, cost, and inability to
individualize therapy. A clinical-level approach, whereby people could be counseled about
the potential risks and benefits of taking a Polypill and could be monitored, might be more
acceptable to physicians than the population-level approach. The goal of this study was to
examine US physicians’ knowledge and attitudes regarding a Polypill approach with
particular focus on whet her physicians would prescribe a Polypill for primary prevention to
patients at varying levels of increased cardiovascular risk.
METHODS
Overall Design
This study was a web-based survey of a national sample of family physicians, general
internists, and cardiologists. The survey was designed by the investigators and revised after
pretesting among a convenience sample of family physicians, general internists, and
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cardiologists. Some items were modified from a questionnaire used in a Polypill study in Sri
Lanka(Soliman EZ et al, Wake Forest University, unpublished study, 2010). This study was
approved by the Institutional Review Board of the University of North Carolina at Chapel
Hill.
Study Sample and Invitations to Participate
Personalized invitation letters were mailed to 8623 physicians randomly selected from
databases of members of the American Academy of Family Physicians and the American
College of Physicians. These letters described that the survey would ask about new ideas in
CVD prevention and pro vided instructions for accessing it online. An individualized
identification code allowed tracking of non-respondents. At two and four weeks after the
initial invitation, non-respondents were mailed reminder letters. As an incentive to
participate, physicians could have their name entered into a drawing for one of two $500 gift
cards.
A total of 1238 physicians participated in the survey. Respondents who indicated they do not
see patients in the office setting (n=251) or whose specialty was not family medicine,
general internal medicine, or cardiology (n=55) were excluded. Seventy-four letters were
returned as undeliverable, including 8 because the intended recipient was deceased, and 3
because of delivery refusal. The adjusted response rate was 15%. The final sample consisted
of 390 family physicians, 272 general internists, and 290 cardiologists.
Variables
Data obtained included self-rated knowledge about the Polypill, factors considered
important to the decision to prescribe a Polypill, and level of agreement with the idea that
CVD risk factors would not need monitoring in patients receiving the Polypill. The
numerical scale for items ranged from 0 to 5, with 0 being lowest level (of knowledge,
agreement or importance) and 5 being the highest. For reporting associations with
acceptance, self-rated Polypill knowledge and ratings of perceptions of problems with
adherence to CVD prevention medications were dichotomized at ≥75th percentile of the
sample. In order to assess acceptance of a clinical approach to using a Polypill, respondents
were asked whether they would be likely to prescribe a Polypill for primary prevention to
patients at moderate CVD risk and high CVD risk (not otherwise defined) . For these items,
respondents were told to assume that the Polypill halved the risk of CVD events.
Information on specialty type, amount of patient care time, year in practice, type of practice
setting, and region of the country was also collected.
Analysis
Responses to each of the items were tabulated and differences were compared by respondent
characteristics. Testing for significant differences was performed using analysis of variance
for numerically-scaled outcomes and chi-square for categorical outcomes. Because of
multiple comparisons, statistically significant differences were defined as a p-value <0.01.
Characteristics of physicians who indicated they would “definitely” or “probably” prescribe
a Polypill for primary prevention were compared in unadjusted analyses and then by logistic
regression to adjust for specialty, years in practice, region of country, self-rated knowledge
and perceptions of patients’ adherence to risk-reducing medications. All analyses were
performed using Stata 10 .1 software (StataCorp, College Station, TX).
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Most respondents were male (74%), in practice ≥10 years (78%), and spent >50% time in
office-based patient care (71%) (Table 1). The most common practice type was small group
practice (2 to 9 clinicians). Family physicians and general internists spent more time in
office-based care than cardiologists. Cardiologists were more likely to be in practice for a
longer time frame.
Knowledge and Attitudes about Polypill
Self-rated knowledge about the Polypill ranged from 0(lowest) to 5 (highest) with a mean of
2.0. Cardiologists’ self-rated knowledge (2.7) was higher than that reported by family
physicians (1.5) and general internists (1.9) (p<0.0001) (Table 2). In terms of factors
important in the decision to prescribe a Polypill, respondents rated cost, degree of CVD
event risk reduction, and side effects nearly equally important with means of 4.3, 4.4, and
4.3, respectively. Importance of patient’s likely adherence and ability to modify doses were
rated slightly less important. Among respondents of all three specialties there was low
agreement (mean 1.0) with the idea to forgo routine monitoring of CVD risk factors in
patients receiving the Polypill.
Acceptance of Prescribing Polypill
Assuming the Polypill halved the risk of cardiovascular events, 41.1% (95% CI 37.9%–
44.2%) of respondents would “definitely” prescribe it and 41.4% (95% CI 38.2%–44.5%)
would “probably” prescribe it for high-risk patients(Table 3) . There was greater uncertainty
among respondents about whether they would prescribe the Polypill for moderate risk
patients. Still, 50.1% (95% CI 46.9%–53.3%) indicated that they “probably” would
prescribe the Polypill to moderate risk patients, and 12.3% (95% CI 10.1%–14.4%)
indicated they would “definitely” prescribe it to moderate risk patients . When asked
whether the Polypill should be available without a prescription assuming that a well-done
large clinical trial showed that it halved the risk of CVD events and it was approved for use
in the US, 89.2% of respondents indicated “no.”
Characteristics of Physicians who would Prescribe Polypill
Physicians who indicated that they would “definitely” or “probably” prescribe the Polypill
to high risk patients as primary prevention were somewhat more likely to be in practice 10
to 19 years, live in the South, and believe that adherence to risk reducing medications was a
problem in their practice (Table 4). Cardiologists were somewhat more likely than general
internists and family physicians to be willing to prescribe Polypill for moderate risk patients
(68.7% vs 61.7% vs 58.3%, p=0.02). Physicians with higher self-rated Polypill knowledge
were more likely to be willing to prescribe it for moderate risk patients (73.2% vs 54.7%,
p<0.001). Other characteristics of physicians who would prescribe Polypill for moderate risk
patients were similar to characteristics of those who would prescribe to high risk patients.
In adjusted models (Table 5), the factors associated with physicians’ acceptance of
prescribing a Polypill were self-rated knowledge about the Polypill and region of country.
Physicians with self-rated knowledge about the Polypill at ≥75th percentile were more likely
to indicate they would prescribe it as primary prevention for moderate risk (OR 2.16; 95%
CI 1.60–2.93) and high-risk (OR 1.57; 95% CI 1.07–2.32) patients. Physicians practicing in
the South were also more likely to indicate that they would prescribe the Polypill.
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This study is the first to the authors’ knowledge to examine acceptance of a Polypill
approach among a sample of US physicians. The findings can be summarized as follows:(1)
based on risk/benefit tradeoff there is a high level of acceptance for prescribing a Polypill
for primary prevention to high risk patients and a moderate level of acceptance for
prescribing it to moderate risk patients, (2) physicians consider multiple relevant factors
equally important when deciding on whether they would prescribe a Polypill, (3) self-rated
knowledge about the Polypill is low, and higher knowledge is associated with greater
acceptance, (4) perceptions of problems with adherence to CVD risk-reducing medications
do not appear to be associated with greater acceptance, (5) physicians would prefer some
ability to modify doses of a Polypill, and (6) physicians do not favor forgoing risk factor
monitoring in patients taking a Polypill.
As initially proposed, the Polypill would be a population level strategy rather than a clinical
one (Wald and Law, 2003). That is, it would be taken by all adults using some non-clinical
criterion such as age (e.g., ≥55 years) without any known CVD (and who had no
contraindication to its components) (Wald and Law, 2003; Wald and Wald, 2010). The
clinical monitoring of risk factor levels and routine assessments for side effects (including
laboratory parameters) would be major barriers to using such a strategy as would the need to
see a physician to obtain a prescription for the Polypill. In other words, requiring the person
interested in taking the Polypill to be a “patient” may limit its population-level potential
(Wald and Wald, 2010). However, US physicians currently have very low agreement with
the idea that CVD risk factors would not need routine monitoring in those taking the
Polypill. Additionally, US physicians did not feel that the Polypill should be available
without a prescription. Physicians were not asked to rate their level of agreement with the
possibility of having the Polypill available by other means (e.g., pharmacists who could
dispense the Polypill after an appropriate screening) (Wald and Wald, 2010). Nevertheless,
the physicians sampled seemed generally unwilling to endorse a population-based approach
to cardiovascular prevention, but could envision the implementation of a more clinical one.
The clinical type of Polypill approach that physicians in this sample find acceptable still
would offer many advantages. While patients at high risk usually have their risk addressed
because of their inherently higher level of risk factors, many people at moderate risk are not
receiving appropriate risk-reducing therapies, particularly in combination(Persell et al,
2006) . It is for this group, estimated to be about 13% of the US adult population, that the
Polypill could be targeted clinically(Ajani et al, 2006). The use of global CVD risk (e.g.,
Framingham-based) assessments could facilitate such an approach. Global risk takes into
account the combined contributions of the major risk factors (including age), and can be
used by clinicians to guide preventive pharmacotherapy without reliance on threshold BP
and cholesterol levels (Pearson et al, 2002). As such, it would be important that the Polypill
not be viewed as a pill for “treatment” of risk factors. Rather, its indication should be for
“prevention” of CVD.
This study showed that physicians with higher self-rated knowledge about the Polypill have
greater acceptance of prescribing a Polypill, particularly to patients at moderate CVD risk.
Specific knowledge questions were not included in this study, however. Thus, it is not
known what particular understandings about the Polypill approach influenced the
physicians’ acceptance. Respondents practicing in the South were somewhat more likely to
indicate that they would “probably” or “definitely” prescribe the Polypill for primary
prevention. This association may be related to the greater burden of CVD seen in the South
(e.g., the “Stroke Belt”) (Lanska and Kuller, 1995).
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The most important limitation of this study is the low response rate. If attitudes and
acceptance as reported by physicians who responded are different from responses that would
be reported by physicians who did not respond, then our results will be biased. If physicians
who chose to respond to the survey were more passionate about CVD prevention, they might
also be more accepting of a Polypill. In such a case our results will overestimate the
acceptance of a Polypill. It is also possible that those especially opposed to the Polypill idea
participated more than physicians whose opinions were in favor of or neutral towards the
idea. In such an instance, our findings would underestimate the level of acceptance.
Whether or not the Polypill would contain aspirin was not specified. In the original Polypill
description, aspirin was included as a component(Wald and Law, 2003) . However, the
efficacy of aspirin in primary prevention of CVD has been called into question(AT T, 2009;
Fowkes et al, 2010; Ogawa et al, 2008). Further, the use of aspirin for CVD prevention
needs to be weighed against the risk of gastrointestinal bleeding (Wolff et al, 2009). It is not
known whether respondents considered such issues in formulating their answers, or whether
respondents’ acceptance would differ between a Polypill containing aspirin and one that did
not.
CONCLUSIONS
US physicians’ acceptance of a clinical approach to using Polypill for CVD prevention
appears fairly high, but our findings suggest that US physicians are not ready to support a
true population level Polypill approach. A clinical strategy using a Polypill for primary
prevention of CVD in the US has tremendous potential and is worthy of study.
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Table 4
Characteristics of Physicians who would “Definitely” or “Probably” Prescribe Polypill for Primary Prevention
of Cardiovascular Disease
Moderate risk patients p-value High risk patients p-value
% %
Specialty 0.02 0.42
 Family medicine 58.3 84.0
 General internal medicine 61.7 82.7
 Cardiology 68.7 80.1
Sex 0.43 0.63
 Male 62.9 82.7
 Female 60.0 81.3
Years in practice 0.04 0.05
 ≥ 20 64.2 80.8
 10–19 66.9 89.1
 <10 55.3 83.4
Region of country 0.02 0.04
 Northeast 61.3 82.8
 South 68.3 86.4
 Midwest 61.4 81.3
 West 53.7 76.1
Time spent in office-based patient care 0.33 0.62
 ≥ 75% 61.8 83.3
 Between 50% & 75% 68.7 82.1
 50% 58.2 83.8
 Between 25% & 50% 64.9 82.5
 <25% 56.2 76.4
Practice setting 0.89 0.06
 Solo practice 66.4 83.6
 Small group (2–9 clinicians) 61.4 87.3
 Large single specialty group (10+ clinicians) 64.6 79.1
 Large multi-specialty group (10+ clinicians) 59.2 76.3
 Academic group 61.8 82.3
 Other 62.3 77.1
Self-rated Polypill knowledge ≥75th percentile <0.001 0.06
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Moderate risk patients p-value High risk patients p-value
% %
 Yes 73.2 85.3
 No 54.7 80.4
Adherence to BP medications a problem in practice* 0.07 <0.001
 Yes 65.7 87.9
 No 59.7 78.5
Adherence to lipid lowering medications a problem in practice* 0.05 0.001
 Yes 65.4 86.9
 No 59.1 78.3
Adherence to aspirin a problem in practice* 0.02 0.01
 Yes 66.6 86.0
 No 58.9 79.7
*
Based on being at or above 75th percentile of sample in response to question, “On a scale from 0 to 5, where 0 indicates not a problem at all and 5
indicates an extremely big problem, how big of a problem is nonadherence to [the medication] in your practice?” Physicians were surveyed in the
United States from February to March 2010
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Table 5
Independent Associations* of Characteristics of Physicians who would “Definitely” or “Probably” Prescribe
Polypill for Primary Prevention of Cardiovascular Disease
Moderate risk patients High risk patients
OR 95% CI OR 95% CI
Specialty
 Family medicine ref ref
 General internal medicine 1.04 0.73–1.48 0.91 0.57–1.45
 Cardiology 1.22 0.83–1.80 0.69 0.43–1.12
Years in practice
 ≥ 20 1.18 0.81–1.72 0.89 0.55–1.46
 10–19 1.48 0.94–2.34 1.54 0.81–2.94
 <10 ref ref
Region of country
 Northeast 1.36 0.89–2.07 1.75 1.05–2.94
 South 1.98 1.33–2.96 2.20 1.34–3.62
 Midwest 1.52 1.00–2.31 1.57 0.95–2.60
 West ref ref
Self-rated Polypill knowledge ≥ 75th percentile
 Yes 2.16 1.60–2.93 1.57 1.07–2.32
 No ref ref
Adherence to BP medications a problem in practice**
 Yes 1.03 0.72–1.48 1.48 0.93–2.36
 No ref ref
Adherence to lipid lowering medications a problem in practice**
 Yes 1.09 0.77–1.54 1.29 0.83–2.00
 No ref ref
Adherence to aspirin a problem in practice**
 Yes 1.31 0.95–1.81 1.13 0.74–1.71
 No ref ref
*
Adjusted for all characteristics in table
**
Based on being at or above 75th percentile of sample in response to question, “On a scale from 0 to 5, where 0 indicates not a problem at all and
5 indicates an extremely big problem, how big of a problem is nonadherence to [the medication] in your practice?” Physicians were surveyed in the
United States from February to March 2010.
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